Literature DB >> 28826172

Evaluation of pretreatment red cell distribution width in patients with multiple myeloma.

Jing Wang1,1, Xin Xie1,2,1, Feng Cheng1, Xin Zhou1, Jun Xia1, Xifeng Qian1, Lingling Wang1, Hongfeng Guo1.   

Abstract

BACKGROUND: Red blood cell distribution width (RDW) has been reported as an inflammatory biomarker and a predictor of prognosis in different types of cancer. However, the role of RDW at diagnosis in patients with multiple myeloma (MM) has been less explored.
OBJECTIVE: We aimed to investigate the association between RDW and the response to treatment and overall survival (OS) in patients with MM.
METHODS: We retrospectively analyzed the data for 196 MM patients between January 1, 2007 and December 31, 2015. Kaplan-Meier analysis and Cox regression model were used.
RESULTS: High RDW values were associated with lower platelet count, lower hemoglobin levels, lower albumin levels, and higher lactate dehydrogenase (LDH) level. Among the entire cohort, the overall response rates (ORR) and complete response (CR) rate of initial therapy were markedly higher in the low-RDW group compared to the high-RDW group. RDW was significant lower in CR in comparison to Non-CR groups in patients treated with bortezomib-based regimens as induction therapy. The patients with low-RDW at diagnosis had better OS when compared to those with high-RDW.
CONCLUSIONS: Elevated RDW was associated with worse survival in patients with MM and could predict treatment responses. Further larger and prospective studies are required.

Entities:  

Keywords:  Multiple myeloma; prognostic; red cell distribution width; survival

Mesh:

Substances:

Year:  2017        PMID: 28826172     DOI: 10.3233/CBM-170032

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  9 in total

1.  Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis.

Authors:  Takao Yogo; Kiyoshi Okazuka; Junichiro Nashimoto; Yui Uto; Kota Sato; Kanji Miyazaki; Mizuki Ogura; Yumiko Yoshiki; Yu Abe; Nobuhiro Tsukada; Tadao Ishida; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2019-06-24       Impact factor: 2.490

2.  Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis.

Authors:  Lisha Ai; Shidai Mu; Yu Hu
Journal:  Cancer Cell Int       Date:  2018-04-23       Impact factor: 5.722

3.  Prognostic significance of the red blood cell distribution width that maintain at high level following completion of first line therapy in mutiple myeloma patients.

Authors:  Yongyong Ma; Zhouxiang Jin; Shujuan Zhou; Haige Ye; Songfu Jiang; Kang Yu
Journal:  Oncotarget       Date:  2018-01-10

4.  The association and diagnostic value of red blood cell distribution width in colorectal cancer.

Authors:  Cheng Shi; Mingzhi Xie; Lihua Li; Kezhi Li; Bang-Li Hu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 5.  Prognostic role of pretreatment red blood cell distribution width in patients with cancer: A meta-analysis of 49 studies.

Authors:  Peng-Fei Wang; Si-Ying Song; Hang Guo; Ting-Jian Wang; Ning Liu; Chang-Xiang Yan
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

6.  Preoperatively elevated RDW-SD and RDW-CV predict favorable survival in intrahepatic cholangiocarcinoma patients after curative resection.

Authors:  Xingchen Li; Qichen Chen; Xinyu Bi; Jianjun Zhao; Zhiyu Li; Jianguo Zhou; Zhen Huang; Yefan Zhang; Rui Mao; Hong Zhao; Jianqiang Cai
Journal:  BMC Surg       Date:  2021-03-01       Impact factor: 2.102

7.  Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study.

Authors:  Xia-Li Mao; Ya-Ming Xi; Zi-Jian Li; Ming-Feng Jia; Ming Li; Li-Na Wang; Long Zhao; Hao Zhang
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

8.  Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis.

Authors:  Xiaomin Chen; Jiayue Liu; Jialin Duan; Hao Xiong; Yang Liu; Xinwen Zhang; Chunlan Huang
Journal:  BMC Cancer       Date:  2022-07-19       Impact factor: 4.638

9.  [The effect of peripheral blood cell score on the prognosis of multiple myeloma patients treated with bortezomib].

Authors:  L Qiu; X Y Han; D H He; F Zhu; Y Zhao; W W Zhu; G F Zheng; Y Yang; W W Wu; Z Cai; X C Yang; J S He
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.